Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesBenefits of Pharmacogenomics in Drug Development-Earlier Launch of Drugs and Less Adverse Events
The Journal of Medical Systems, 04/16/09
Ohashi W et al. - PGx enables earlier launch of a drug with less cost, representing benefit to pharmaceutical companies, patients and public as a whole. Currently, pharmaceutical companies are reluctant to introduce pharmacogenomics (PGx) in their practice, since cost–benefit of PGx is obscure and methodology to use PGx in drug development has not been fully established yet.
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Medicare cracks down on false claims
Medical Economics, 11/02/09
2009 earnings survey: How do you compare
Medical Economics, 09/29/09
How sensitive is physician performance to alternative compensation schedules? Evidence from a large network of primary care clinics
Health Economics, 10/29/09
Sponsor
Article Search
Sponsor
Sponsor